Home › Small Cell Lung Cancer › Virginia
Small Cell Lung Cancer clinical trials in Virginia
30 studies for Small Cell Lung Cancer are looking for participants at sites in Virginia.
Cities in Virginia
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
- Virginia Cancer Specialists - Fairfax /ID# 278298, Fairfax
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07155174The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- University of Virginia, Charlottesville
- NEXT Virginia, Fairfax
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Oct 1, 2026 · NCT06586957Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
- Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Blacksburg
- Virginia Oncology Associates, Chesapeake
- Virginia Oncology Associates, Hampton
- and 8 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07226999A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- Blue Ridge Cancer Care - Blacksburg /ID# 281583, Blacksburg
- Virginia Cancer Specialists - Fairfax /ID# 280710, Fairfax
- Shenandoah Oncology /ID# 280699, Winchester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07365241A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Inova Schar Cancer Institute Clinical Trials, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07488676Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
- NEXT Virginia, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07730021A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
- Site 1002, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07407933BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07625644A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07218146A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Oncology & Hematology Associates of Southwest Virginia, Inc., Roanoke
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06646276AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Fairfax
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Sep 4, 2026 · NCT07038343Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Virginia Cancer Specialists, Fairfax
- Hematology Oncology Associates of Fredericksburg, Inc., Fredericksburg
- Virginia Commonwealth University School of Medicine, Richmond
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT06712355Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
- Universtiy of Virginia, Charlottesville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07057791A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT06892548Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
- Next Virginia, Fairfax
RecruitingPhase 1
Ages 18 to 99 · All sexes · Updated Aug 21, 2026 · NCT07531095A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
- Oncology & Hematology Associates of Southwest Virginia, Blacksburg
- Virginia Cancer Specialists Research Institute, Fairfax
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06095505A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07749586DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Virginia Commonwealth University Health- Adult Outpatient Pavilion, Richmond
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT05882058A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- NEXT Virginia, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT05652686A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
- NEXT Oncology Virginia, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 9, 2026 · NCT07174583Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
- University of Virginia Comprehensive Cancer Center, Charlottesville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 26, 2026 · NCT07149363A Study of LY4175408 in Participants With Advanced Cancer
- NEXT Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT07046923AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
- NEXT Oncology Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 2, 2026 · NCT07454642MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
- University of Virginia Health System, Charlottesville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 29, 2026 · NCT05903092Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
- NEXT Oncology Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 7, 2026 · NCT07424547Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
- VCU Community Memorial Health Center, South Hill
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 30, 2026 · NCT06769126Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- NEXT Virginia, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Feb 18, 2026 · NCT07030257A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 102, Fairfax
- Research Site 112, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 21, 2025 · NCT05914116From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.